Preliminary Programme

Protonotarios Workshop on Treatable Inherited CV Diseases

Challenging: Perry Elliott, J. Kaski

Thursday 04.06.2026 || 16.00-20.00 | ONASSIS HOSPITAL

16.00-17.00	**HYPERTROPHIC CARDIOMYOPATHY AND MYOSIN INHIBITORS** ▪ HCM1 ▪ HCM2 ▪ HCM3
17.00-18.00	**DCM/NDLVC CARDIOMYOPATHY** ▪ DSP CARDIOMYOPATHY ▪ FILAMIN-C CARDIOMYOPATHY ▪ RBM20 CARDIOMYOPATY
18.00-19.00	**HYPERTROPHIC CARDIOMYOPATHY PHENOCOPIES** ▪ FABRY DISEASE ▪ ATTR-AMYLOEIDOSIS ▪ NOONAN /RASOPATHIES
19.00-20.00	**CARDIOMYOPATHY AND SYSTEMIC DISEASES** ▪ FRIEDRICH ATAXIA ▪ DUCHENNE CARDIOMYOPATHY ▪ SARCOIDOSIS

Preliminary Programme

International Conference on Genetics and Precision Medicine in Cardiology

4-6 June 2026 | Acropolis Museum, Athens, Greece

Friday 05.06.2026

08.00-09.00	**REGISTRATIONS**
09.30-10.00	**OPENING SESSION** Welcome and Chairs: **Panos Vardas, Aris Anastasakis, Perry Elliott, John Boletis** ▪ Setting the scene: The Greek Network for inherited disease ▪ ICON: Ensuring our future health systems leave no family behind ▪ World Heart Federation: 2026-the year of forgotten cardiovascular diseases ▪ The view from Europe: The EU Cardiovascular Plan and Opportunities for Precision Cardiology
10.30-11.30	**SESSION** **Genetic Testing is Changing the Rules** ▪ From Family History to Whole-Genome Sequencing: when, who, how? ▪ Variants of Uncertain Significance: Clinical Clue or Diagnostic Trap? ▪ Can Genetic Testing Save Lives? Discussion
11.30-12.00	**BREAK**
12.30-14.00	**SESSION Hidden in Heart Failure** *Goal: To describe current approaches to diagnosis of cardiomyopathies in heart failure practice and to explore enhanced diagnostic pathways and opportunities for aetiology-based therapies.* ▪ Unmasking the Genetic Causes of heart failure (From one too many diseases) ▪ HFpEF or cardiomyopathy: two sides of the same coin? ▪ Precision treatments for cardiomyopathy: here at last? Discussion

14.00-14.30	**KEYNOTE SPEECH** Gene therapy in Cardiomyopathies: What are the realities?
14.30-15.00	**LUNCH BREAK**
15.30-17.00	**SESSION** **Highlights from the Network and registries** ▪ Amyloidosis: A new era ▪ Fabry disease, a curable entity ▪ Genetic cardiac diseases: Family matters ▪ Familial amyloidosis
17.00-18.30	**SESSION** **ICDs and Channelopathies: yes or no?** *Goal: To describe current approaches to risk evaluation and treatment, emphasizing gaps in evidence and controversies* ▪ Long QT Syndrome: One Interval, Multiple Genetic Stories ▪ Brugada Syndrome: Genotype, Phenotype, or Fever? ▪ CPVT: A Structurally Normal Heart with Lethal Potential Discussion
18.30-19.00	**BREAK**
19.30-20.30	**SESSION** **Highlights from the network** ▪ HCM, myosin inhibitors and prognosis ▪ DCM /NDLVC, Genetics and prognosis ▪ Myocarditis and noise in the family
20.30-21.00	**WHF LECTURE** Introduction From Declarations to Implementation: Bold Measures to Reduce the Cardiovascular Burden of Non-Communicable Diseases

Saturday 06.06.2026

8.00-9.00	**Registrations**
09.00-10.00	**SESSION** **Arrhythmogenic Cardiomyopathy: A Name Out of Context?** *Goal: To progress from a historical debate on terminology to an etiology-focused approach to disease management* ▪ What Is Arrhythmogenic Cardiomyopathy?, A Guideline perspective ▪ 'Non-ischaemic' Myocardial fibrosis: does genetic testing help? ▪ Immunology of ARVC
10.00-10.30	**KEYNOTE SPEECH** Will genetics and imaging replace cardiac pathology?
10.30-11.00	**KEYNOTE LECTURE** State of Art in Familial Aortopathies
11.00-12.00	**SESSION** **Highlights from the Network** Panel Discussion: Gene-specific management for aortopathy: Who and when?
12.00-12.30	**BREAK**
12.30-13.30	**SESSION** **Syndromic forms of cardiomyopathy** ▪ Rasopathies ▪ Muscular Dystrophies ▪ Mitochondrial ▪ Fabry Disease
13.30-14.30	**SESSION** **Debate: Use of the term rare to describe cardiovascular disease is helpful in promoting better diagnosis and management**

14.30-15.30	**LUNCH**
15.30-16.30	**SESSION** **Introductory Speech** **Introductory Speech: Precision Medicine and equal access** **Introductory Speech: AI and Digital Governance/Greece**
16.30-17.30	**PANEL DISCUSSION** **How do we ensure equal access to emerging therapies in Cardiovascular Medicine?**
17.30-18.00	**KEYNOTE SPEECH** Genetics and AI: The new era
18.00-18.30	**BREAK**
18.30-19.30	**SESSION** **Genetics and Athletes** ▪ Dilated Heart: Athlete's Heart or Dilated Cardiomyopathy? ▪ Arrhythmias in the Young Athlete: Benign or Malignant? ▪ Ph(–)/G(+) and Athletic Activity – Does It Matter?
19.30-20.00	**KEYNOTE SPEECH** **Medicine and Democracy**
20.00-20.30	**CLOSING REMARKS** **Perry Elliott, Aris Anastasakis, Panos Vardas**